CC-98633

· Juno Therapeutics, a subsidiary of Celgene

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CC-98633, covering 2024-07-26 to 2024-07-26. Get the full timeline:

Most recent: Clinical Trial Update: A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma [Phase 1]

See pricing